The Clinical Push for Smarter, Faster Depression Treatment
A new review published in Psychiatric Times is drawing attention to how clinicians should be managing NMDA receptor antagonists — the drug class that includes both IV ketamine and intranasal esketamine (Spravato) — when used for treatment-resistant depression (TRD). The core message from clinicians: stop waiting and hoping. Use data, track symptoms systematically, optimize doses proactively, and switch protocols sooner when results aren't materializing.
For patients considering ketamine therapy through an online provider in 2026, this guidance has real implications — not just for how your treatment should be structured, but for how you evaluate whether your provider is meeting the emerging standard of care.
What the Research Actually Says
The Psychiatric Times review focuses on side effect profiles and discontinuation rates — two metrics that matter enormously to patients but are often underemphasized during the decision-making process. NMDA antagonists like ketamine and esketamine can produce dissociative symptoms, elevated blood pressure, nausea, dizziness, and in some cases, feelings of depersonalization during and shortly after treatment sessions. These effects are typically transient, resolving within hours, but the review notes that they are a leading driver of early discontinuation.
Discontinuation is a significant issue in TRD treatment. Patients who stop prematurely — often due to unmanaged side effects or a perceived lack of early response — rarely achieve the remission that sustained treatment could provide. The clinical guidance emphasizes that providers need to anticipate and actively manage these experiences, not simply reassure patients after the fact.
On the efficacy side, clinicians are now being urged to use validated measurement tools — particularly the PHQ-9, a standardized nine-question depression screening instrument — at regular intervals to track response. The goal is to establish an objective evidence trail that informs dosing decisions and protocol changes, rather than relying solely on patient self-report or clinical intuition.
Why This Matters for Online Ketamine Patients
The telehealth ketamine space has expanded dramatically over the past several years, and with that growth comes a wide range of provider quality. Some platforms offer robust intake screening, ongoing psychiatric oversight, and structured follow-up — others offer little more than a prescription and a shipping box. The clinical standards being reinforced in this review help clarify what "good care" actually looks like, and patients can use that framework to ask better questions before committing to a provider.
Systematic symptom tracking: Is your provider using PHQ-9 or a comparable validated tool at each check-in? If your telehealth platform only asks how you're feeling in a general sense without structured measurement, that's a gap. Remission-focused care requires objective benchmarks, not just subjective impressions.
Side effect documentation: Are dissociative experiences, blood pressure changes, nausea, or mood shifts being recorded session by session? Responsible providers collect this data because it informs dose titration. A platform that doesn't track side effects can't make informed adjustments — and can't identify when a patient is trending toward discontinuation before it happens.
Willingness to switch or adjust: The review specifically flags that clinicians should be willing to optimize doses or transition patients to alternative protocols sooner rather than later when response is inadequate. This requires a provider who is actively engaged with your case — not one who rubber-stamps refills. For at-home ketamine patients, this means having a prescriber who reviews your progress data and initiates protocol conversations, not one who waits for you to reach out.
Safety screening rigor: The side effect profile of ketamine — including cardiovascular effects and dissociation — makes pre-treatment screening essential. History of psychosis, active substance use disorder, uncontrolled hypertension, or certain cardiac conditions can raise the risk profile significantly. Online providers who conduct thorough intake evaluations, including medical history review and contraindication screening, are following the safety standards this research reinforces.
Key Takeaway for Patients
Emerging clinical guidance makes clear that ketamine treatment for depression should be data-driven — not passive. If your provider isn't tracking your PHQ-9 scores, documenting your side effect experiences session by session, and actively discussing dose adjustments or protocol changes when response stalls, you may not be receiving the standard of care the evidence now supports. Before starting or continuing treatment, ask your provider directly how they measure progress and how they respond when early sessions don't produce results.
What to Ask Before Choosing a Provider
This research gives patients a concrete checklist for evaluating online ketamine providers. Here are the questions worth raising during an initial consultation or before signing up for a platform:
- How do you track treatment response? Look for mention of PHQ-9, GAD-7, or other validated tools used at defined intervals.
- How are side effects documented? Each session should involve structured side effect reporting, not just a general check-in.
- What triggers a protocol change? Providers should have clear criteria for when they adjust dose, frequency, or route of administration — or refer out for higher-level care.
- What's your discontinuation support process? If a patient wants to stop treatment, is there a taper plan? A follow-up call? Or does the relationship simply end?
- Who reviews my data between sessions? Ideally, a licensed prescriber — not just a care coordinator — should be reviewing your symptom tracking data before each refill or session authorization.
The standard of care for NMDA antagonist therapy in TRD is becoming more defined, and that's good news for patients. It means the field is maturing — and that you have more grounds to expect, and demand, structured and responsive care. Use this research as a baseline. The providers who are following it are the ones worth trusting with your treatment.
Share